Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudia Fleissner

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
European Journal of Haematology|August 23, 2006
Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatmentUlrike Heider, Martin Kaiser, Christian Müller, et al.
Journal of Cancer Research and Clinical Oncology|September 4, 2008
Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated I kappaB kinaseIvana von Metzler, Holger Krebbel, Ulrike Kuckelkorn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myelomaUlrike Heider, Corinna Langelotz, Christian Jakob, et al.
Journal of Cancer Research and Clinical Oncology|July 10, 2003
Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletionIvana Zavrski, Cord Naujokat, Kathrin Niemöller, et al.
Journal of Cancer Research and Clinical Oncology|June 19, 2004
Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cellsUlrike Heider, Ivana Zavrski, Christian Jakob, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2003
Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiographyChristian Jakob, Ivana Zavrski, Ulrike Heider, et al.
European Journal of Haematology|November 17, 2007
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphomaUlrike Heider, Ivana von Metzler, Martin Kaiser, et al.
European Journal of Haematology|March 12, 2008
Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myelomaMartin Kaiser, Maren Mieth, Peter Liebisch, et al.
Psycho-Oncology|May 9, 2012
Development of an EORTC quality of life phase III module measuring cancer-related fatigue (EORTC QLQ-FA13)Joachim Weis, Juan Ignacio Arraras, Thierry Conroy, et al.
Blood|November 11, 2006
Circulating proteasome levels are an independent prognostic factor for survival in multiple myelomaChristian Jakob, Karl Egerer, Peter Liebisch, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
European Journal of Haematology|August 23, 2006
Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatmentUlrike Heider, Martin Kaiser, Christian Müller, et al.
Journal of Cancer Research and Clinical Oncology|September 4, 2008
Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated I kappaB kinaseIvana von Metzler, Holger Krebbel, Ulrike Kuckelkorn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myelomaUlrike Heider, Corinna Langelotz, Christian Jakob, et al.
Journal of Cancer Research and Clinical Oncology|July 10, 2003
Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletionIvana Zavrski, Cord Naujokat, Kathrin Niemöller, et al.
Journal of Cancer Research and Clinical Oncology|June 19, 2004
Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cellsUlrike Heider, Ivana Zavrski, Christian Jakob, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2003
Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiographyChristian Jakob, Ivana Zavrski, Ulrike Heider, et al.
European Journal of Haematology|November 17, 2007
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphomaUlrike Heider, Ivana von Metzler, Martin Kaiser, et al.
European Journal of Haematology|March 12, 2008
Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myelomaMartin Kaiser, Maren Mieth, Peter Liebisch, et al.
Psycho-Oncology|May 9, 2012
Development of an EORTC quality of life phase III module measuring cancer-related fatigue (EORTC QLQ-FA13)Joachim Weis, Juan Ignacio Arraras, Thierry Conroy, et al.
Blood|November 11, 2006
Circulating proteasome levels are an independent prognostic factor for survival in multiple myelomaChristian Jakob, Karl Egerer, Peter Liebisch, et al.
Pageof 2